Avalon GloboCare Corp. (NASDAQ:ALBT – Get Free Report) saw a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,541,639 shares, an increase of 1,180.8% from the June 30th total of 120,361 shares. Currently, 14.0% of the company’s stock are short sold. Based on an average daily volume of 4,865,720 shares, the days-to-cover ratio is presently 0.3 days.
Avalon GloboCare Stock Down 1.1%
Shares of Avalon GloboCare stock traded down $0.00 on Friday, reaching $0.28. The company’s stock had a trading volume of 9,336,703 shares, compared to its average volume of 3,170,642. Avalon GloboCare has a 52 week low of $0.21 and a 52 week high of $4.74. The firm’s fifty day simple moving average is $0.32 and its two-hundred day simple moving average is $0.57. The company has a market capitalization of $4.05 million, a price-to-earnings ratio of -0.08 and a beta of -0.03.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Avalon GloboCare currently has an average rating of “Sell”.
About Avalon GloboCare
Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.
Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.
Further Reading
- Five stocks we like better than Avalon GloboCare
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.
